Laboratory Medicine
Test Directory / Parathyorid Hormone
Parathyorid Hormone
EDTA
Test | Parathyorid Hormone |
---|---|
Common Abbreviations | PTH |
Profile | NA |
Tube type | EDTA |
Clinical Indication | Quantification of circulating PTH assists in the differential diagnosis of hypercalcemia and hypocalcemia. In conjunction with the measurement of ionized calcium, PTH evaluations can be used to distinguish between patients with hyperparathyroidism, hypoparathyroidism or hypercalcemia of malignancy. The diagnosis of primary hyperparathyroidism, a common cause of hypercalcemia, is confirmed by elevated ionized calcium concentrations and elevated PTH concentrations. PTH levels are also used to assess and manage other metabolic bone disorders including osteoporosis and renal osteodystrophy |
Specimen Type | Blood |
Sample type | Plasma |
Minimum Volume | 1mL |
Special Precautions | EDTA samples should be spun and the plasma separated from the cells within 24 hours of collection. The plasma should then be stored at 4ºC and analysed with 72 hours of collection. |
Stability | Plasma: 2 days at 15 - 25°C, 3 days at 2 - 8°C and 6 months at -20°C |
Turnaround Time | Inpatient: 24 hours Outpatient/ GP: 24 hours |
Laboratory | York and Scarborough |
Reference Interval | 1.6 - 6.9 pmol/L (Quoted by the ,manufacturer) |
Limitations | Analysis should not be performed on haemolysed, icteric or lipaemic samples. The assay is unaffected by biotin < 205 nmol/L or < 50 ng/mL. No interference was observed from rheumatoid factors up to a concentration of 1200 IU/mL. Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration. In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the assay was found. In addition special drugs were tested. No interference with the assay was found. In rare cases, high titres of antibodies to analyte specific antibodies, streptavidin or ruthenium can occur. |
Notes |